Cost variation among antiretroviral drugs: pharamcoeconomical prospective
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20180968Keywords:
Antiretroviral drugs, Drug price control order, Percentage cost variation, Pharmaceutical industryAbstract
Background: Acquired immunodeficiency syndrome (AIDS) is a disorder caused by the human immunodeficiency virus (HIV). Main characteristic feature of AIDS includes severe immunosuppression which leads to opportunistic infections which is a main cause of death and requires a lifelong therapy. There exists wide range of cost variation in antiretroviral drugs that are marketed in India. The current study aims to view the existing situation of antiretroviral drugs, by collecting data about the cost of common antiretroviral drugs available either singly or in combination and to evaluate the difference in cost of different brands of same active drug by calculating percentage cost variation.
Methods: Data for calculating cost ratio and percentage price variation of various antiretroviral drugs was obtained from “Current Index of Medical Specialties” October 2017-January2018.
Results: Zidovudine 100mg shows maximum cost ratio and price variation followed by Lamivudin 100mg in the single drug therapy. Lamivudine 150mg + Zidovudine 300mg shows maximum price variation in combination drug therapy.
Conclusions: Indian market shows wide price variation of different brands of the same generic antiretroviral drug. To decrease the wide cost variation among different brands of antiretroviral drugs; it is time to create awareness among healthcare professionals about impact of cost effectiveness of drug regimen and decrease the financial burden on the patients.
Metrics
References
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. Harrison's Principles of Internal Medicine, 19th Ed. New York, NY: McGraw-Hill; 2015.
World Health Organization [Online]. 2016 [cited 2018 Feb 7]; Available at: URL:http://www.who.int/gho/hiv/en/
National AIDS Control Organization [Online]. 2016 [cited 2018 Feb 10]; Available at: URL:http://naco.gov.in/sites/default/files/NACO%20ANNUAL%20REPORT%202016-17.pdf
Patel D, Thiyagu R, Surulivelrajan M, Patel H, Pandey S. Price variability among the oral antibiotics available in a South Indian Tertiary Care Hospital. J Clin Diagn Res. 2009;3(6):1871-5.
Indian Pharmaceutical Industry [Online]. 2018 [cited 2018 Feb 8]; Available at: https://www.ibef.org/industry/pharmaceutical-india.
Shankar PR, Subish P, Bhandari RB, Mishra P, Saha AC. Ambiguous pricing of topical dermatological products: a survey of brands from two South Asian countries. J Pak Assoc Dermatol. 2006;16:134-40.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160‑3.
Operational Guidelines on Free drug service Initiative. National Health Mission. [Online]. 2012 [cited 2018 Feb 4]; Available at: http://nhm.gov.in/images/pdf/NHM/NHM-Guidelines/Free_Drugs_Service_Intitiative.pdf
Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol. 2015;4:860-3.
Sarkar PK. A rational drug policy. Indian J Med Ethics. 2004;12:30-5.
Roy V, Rewari S. Ambiguous drug pricing: a physician’s dilemma. Indian J Pharmacol. 1998;30:404-7.
Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992;2(6):449-55.
Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care. 1977;15(3):241-50.
Rataboli PV, Dang A. Antimicrobial price variation: conundrum of medical profession! J Postgrad Med. 2007;53(1):72-4.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between differ rent brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.
Dawadi S, Rao BS, Khan GM. Pattern of antimicrobial prescription and its cost analysis in respiratory tract infection. Kathmandu Univ J Sci Eng Technol. 2005;1(1):1-9.
Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.
Jana S, Mondal P. Pharmacoeconomics: the need to sensitize undergraduate medical students. Indian J Pharmacol. 2005;37(5):277-8.
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: A systematic review. PLoS Med. 2007;4(9):e283.
Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med. 1991;115(2):116-21.
Medical Council of India [Online]. 2016 [cited 2018 Feb 10]; Available at: http://www.ipgmer.gov.in/PharmacovigilanceCommittee/MCI_CircularUseofGenericNames20170421.pdf
Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol. 2011;43:131-6.